These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29311633)

  • 1. TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis.
    Peramuhendige P; Marino S; Bishop RT; de Ridder D; Khogeer A; Baldini I; Capulli M; Rucci N; Idris AI
    Sci Rep; 2018 Jan; 8(1):39. PubMed ID: 29311633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
    Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
    Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
    Marino S; Bishop RT; Mollat P; Idris AI
    Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of breast cancer induced bone disease by cancer-specific IKKβ.
    Marino S; Bishop RT; Capulli M; Sophocleous A; Logan JG; Mollat P; Mognetti B; Ventura L; Sims AH; Rucci N; Ralston SH; Idris AI
    Oncotarget; 2018 Mar; 9(22):16134-16148. PubMed ID: 29662632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis.
    Bishop RT; Marino S; Carrasco G; Li B; Allen RJ; Sparatore A; Ottewell PD; Mollat P; Sims AH; Capulli M; Wang N; Idris AI
    Cancer Lett; 2020 Sep; 488():27-39. PubMed ID: 32474152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
    Bishop RT; Marino S; de Ridder D; Allen RJ; Lefley DV; Sims AH; Wang N; Ottewell PD; Idris AI
    Cancer Lett; 2019 May; 450():76-87. PubMed ID: 30790681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression.
    Hu F; Wang C; Guo S; Sun W; Mi D; Gao Y; Zhang J; Zhu T; Yang S
    Biochim Biophys Acta; 2011 Mar; 1809(3):200-10. PubMed ID: 21241837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
    Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
    Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
    Pivetta E; Scapolan M; Pecolo M; Wassermann B; Abu-Rumeileh I; Balestreri L; Borsatti E; Tripodo C; Colombatti A; Spessotto P
    Breast Cancer Res; 2011 Oct; 13(5):R105. PubMed ID: 22032644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer.
    Shah M; Huang D; Blick T; Connor A; Reiter LA; Hardink JR; Lynch CC; Waltham M; Thompson EW
    PLoS One; 2012; 7(1):e29615. PubMed ID: 22253746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo.
    Frantzias J; Logan JG; Mollat P; Sparatore A; Del Soldato P; Ralston SH; Idris AI
    Br J Pharmacol; 2012 Mar; 165(6):1914-1925. PubMed ID: 21955294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
    Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
    Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.
    Zhu M; Liu C; Li S; Zhang S; Yao Q; Song Q
    Sci Rep; 2017 Sep; 7(1):11399. PubMed ID: 28900298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo.
    Marino S; Bishop RT; Carrasco G; Logan JG; Li B; Idris AI
    Calcif Tissue Int; 2019 Aug; 105(2):193-204. PubMed ID: 30929064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
    Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
    Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
    Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.
    Kitayama K; Kawamoto T; Kawakami Y; Hara H; Takemori T; Fujiwara S; Yahiro S; Miyamoto T; Mifune Y; Hoshino Y; Kakutani K; Matsumoto T; Matsushita T; Niikura T; Kuroda R; Akisue T
    Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34713296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.
    Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S
    Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.